公开(公告)号：HK1019338A1

公开(公告)日：2000-02-03

申请号：HK99104433

申请日：1999-10-08

Applicant: SOLVAY PHARM GMBH

Inventor： WALDECK HARALD ,  MEIL JOERG ,  THORMAEHLEN DIRK ,  WURL MICHAEL

IPC: A61K31/675 ,  A61K31/00 ,  A61K31/55 ,  A61K38/00 ,  A61K38/05 ,  A61P9/00 ,  A61P9/04 ,  A61P9/12 ,  C07D223/16 ,  C07F9/38 ,  C07F9/40 ,  C07F9/553 ,  C07K5/06 ,  C07F ,  A61K

Abstract: 3-(1-Phosphonomethyl-cyclopentane-1-carbonylamino)-2,3,4,5-tetrahydro- 2-oxo-1H-1-benzazepine-1-acetic acid derivatives (I) are new. Benzazepine derivatives of formula (I) and their salts are new: R1-R3 = H or biolabile ester residue. An Independent claim relates to the preparation of (I).

公开(公告)号：CA2541867C

公开(公告)日：2012-06-12

申请号：CA2541867

申请日：2004-10-07

Applicant: SOLVAY PHARM GMBH

Inventor： BAUM DOMINIQUE ,  BIELENBERG GERHARD-WILHELM ,  BOEDECKER BERND ,  THORMAEHLEN DIRK

IPC: A61K45/06 ,  A61K31/4172 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/506 ,  A61P9/14

Abstract: The present invention relates to pharmaceutical compositions comprising selective imidazoline receptor agonists combined with angiotensin II receptor blockers. In particular, the present invention relates to pharmaceutical compositions comprising Moxonidine and Eprosartan mesylate. The invention also relates to the use of said compositions in the manufacture of a medicament for the treatment of hypertension, especially in hypertensive patients already suffering from type II diabetes or being susceptible to developing type II diabetes.

公开(公告)号：CA2253997C

公开(公告)日：2009-05-12

申请号：CA2253997

申请日：1998-11-12

Applicant: SOLVAY PHARM GMBH

Inventor： WALDECK HARALD ,  MEIL JOERG ,  WURL MICHAEL ,  THORMAEHLEN DIRK

IPC: A61K31/675 ,  C07F9/553 ,  A61K31/00 ,  A61K31/55 ,  A61K38/00 ,  A61K38/05 ,  A61P9/00 ,  A61P9/04 ,  A61P9/12 ,  C07D223/16 ,  C07F9/38 ,  C07F9/40 ,  C07F9/6558 ,  C07K5/06

Abstract: Compounds having NEP-inhibitory activity, corresponding to the formula I (see formula I) in which R1 is hydrogen or a group forming a biolabile phosphonic acid ester, R2 is hydrogen or a group forming a biolabile phosphonic acid ester and R3 is hydrogen or a group forming a biolabile carboxylic acid ester and physiologically acceptable salts of acids of formula I, and pharmaceutical compositions comprising these compounds.

公开(公告)号：CA2579716A1

公开(公告)日：2006-01-05

申请号：CA2579716

申请日：2005-06-22

Applicant: SOLVAY PHARM GMBH

Inventor： HOELTJE DAGMAR ,  STRAUB MATTHIAS ,  FISCHER YVAN ,  THORMAEHLEN DIRK ,  ZIEGLER DIETER ,  WITTE KLAUS

IPC: A61K31/00 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/55 ,  A61K45/06 ,  A61P9/00 ,  A61P9/12

公开(公告)号：AU2005256634A1

公开(公告)日：2006-01-05

申请号：AU2005256634

申请日：2005-06-22

Applicant: SOLVAY PHARM GMBH

Inventor： THORMAEHLEN DIRK ,  WITTE KLAUS ,  HOELTJE DAGMAR ,  FISCHER YVAN ,  ZIEGLER DIETER ,  STRAUB MATTHIAS

IPC: A61K31/00 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/55 ,  A61K45/06

公开(公告)号：AT295174T

公开(公告)日：2005-05-15

申请号：AT00903681

申请日：2000-02-10

Applicant: SOLVAY PHARM GMBH

Inventor： WILKINS MARTIN R ,  THORMAEHLEN DIRK ,  WALDECK HARALD

IPC: C07D223/16 ,  A61K31/55 ,  A61P9/00 ,  A61P9/12

Abstract: The present invention relates to the use of benzazepine-N-acetic acid derivatives which contain an oxo-group in the alpha-position to the nitrogen atom and are substituted in position 3 by a 1-(carboxyalkyl)cyclo-entylcarbonylamino radical, and their salts and biolabile esters for the treatment of hypertension, particularly for the treatment of certain forms of secondary hypertension, in larger mammals and particularly humans, and for the production of pharmaceutical compositions suitable for this treatment. The cause of the hypertension to be treated may have a wide variety of origins. The invention particularly relates to the treatment of those forms of secondary hypertension which may occur as a result of various non-cardiac diseases.

公开(公告)号：AU2004283047A1

公开(公告)日：2005-05-06

申请号：AU2004283047

申请日：2004-10-07

Applicant: SOLVAY PHARM GMBH

Inventor： BOEDECKER BERND ,  BAUM DOMINIQUE ,  BIELENBERG GERHARD-WILHELM ,  THORMAEHLEN DIRK

IPC: A61K31/506 ,  A61K31/4172 ,  A61K31/4178 ,  A61K31/4184 ,  A61K45/06

Abstract: Pharmaceutical compositions containing selective imidazoline receptor agonists combined with angiotensin II receptor blockers, particularly, pharmaceutical compositions containing Moxonidine and Eprosartan mesylate, as well as the use of such compositions for the treatment of hypertension, especially in hypertensive patients suffering from type II diabetes or susceptible to developing type II diabetes.

公开(公告)号：HU223752B1

公开(公告)日：2005-01-28

申请号：HU9701540

申请日：1997-09-15

Applicant: SOLVAY PHARM GMBH

Inventor： THORMAEHLEN DIRK ,  WALDECK HARALD ,  ROZSA SUSANNA ,  PAPP JULIUS GY

IPC: C07D223/16 ,  A61K31/55 ,  A61P1/00

公开(公告)号：AR036864A1

公开(公告)日：2004-10-13

申请号：ARP000100257

申请日：2000-01-20

Applicant: SOLVAY PHARM GMBH

Inventor： WILKINS MARTIN R ,  WALDECK HARALD ,  THORMAEHLEN DIRK

IPC: C07D223/16 ,  A61K31/55 ,  A61P9/00 ,  A61P9/12

Abstract: Uso de compuestos de la fórmula general (1) en la cual R1 representa un radical fenilalquilo inferior eventualmente sustituido en el ciclo fenilo por alquilo inferior, alcoxi inferior o halógeno, o un radical naftil-alquilo inferior, R2 representa hidrógeno o un radical capaz de formar un éster biolábil, R3 representa hidrógeno o un radical capaz de formar un éster biolábil, y sales fisiológicamente tolerables de los ácidos de la fórmula (1) para la preparación de composiciones farmacéuticas para el tratamiento de la hipertensión, particularmente de aquellas formas de la hipertensión secundaria causadas por condiciones cardíacas en mamíferos superiores y seres humanos.

公开(公告)号：PL184904B1

公开(公告)日：2003-01-31

申请号：PL30700195

申请日：1995-01-30

Applicant: SOLVAY PHARM GMBH

Inventor： SCHOEN UWE ,  BRUECKNER REINHARD ,  MEIL JOERG ,  THORMAEHLEN DIRK

IPC: C07D471/18 ,  A61K31/439 ,  A61K31/445 ,  A61K31/495 ,  C07D471/08 ,  C07D471/10 ,  C07D487/08 ,  C07D487/10

Abstract: Use of 3-benzoyl-3,7-diazabicyclo(3,3,1) -nonane derivs. of formula (I) and their acid addn. salts is claimed in the treatment of disorders of heart rhythm in large mammals and humans. R1 = 1-6C alkyl or 4-7C cycloalkylalkyl; R2, R3 = lower alkyl; or R2+R3 = 3-6C alkylene; R4 = H, halogen, CN, NO2, CF3 or SO2R6; R5 = H, halogen, CF3 or NO2; R6 = F or lower alkyl.